TD Cowen analyst Dan Brennan raised the firm’s price target on PacBio to $19 from $17 and keeps an Outperform rating on the shares. The firm said the Revio pull-thru and a 2023 guidance raise were key positives for 2Q results. The Apton acquisition adds a new future leg of growth though spending/focus here cannot dilute Revio efforts.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on PACB:
- PacBio enters an agreement to acquire Apton Biosystems for $85M upfront
- PacBio Announces Second Quarter 2023 Financial Results
- PacBio reports Q2 adjusted EPS (26c), consensus (32c)
- PacBio Enters into Agreement to Acquire Apton Biosystems to Accelerate the Development of a Next Generation, High Throughput, Short-read Sequencer
- PacBio assumed with an Overweight at JPMorgan